N/A
N=42
e-Motivación: Developing and Pilot Testing an App to Improve Latinos' Screening Colonoscopy Rates
Colorectal Cancer
Bottom Line
View on ClinicalTrials.gov: NCT04987788 ↗Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcome: Primary: Colonoscopy Completion — 19; 19 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Motívate (Behavioral); Video link (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Primary completion
- Apr 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Colonoscopy Completion |
19; 19 | — |
Summary
Among Latinos, a fast growing and underserved population, Colorectal Cancer (CRC) is the third leading cause of cancer death in men and in women. Compared to non-Latino whites, Latinos are less likely to be diagnosed with localized CRC and more likely to be diagnosed with advanced stage disease. Of the recommended CRC screening tests, a colonoscopy allows for both the detection and removal of precancerous and cancerous polyps. Although screening colonoscopies can detect and prevent CRC, more than half of Latinos have not received a screening colonoscopy within the recommended time frame (one screening colonoscopy per ten years).
The purpose of this study is to develop and begin to test an electronically-delivered motivational interviewing progressive web application (e-MI app), called Motívate. The Motívate app will be offered in both English and Spanish to patients who self-identify as Latino/a/x, after they receive a referral for a screening colonoscopy.
Eligibility Criteria
Inclusion Criteria
- Self-identified as Latino/a/x;
- English or Spanish-speaking;
- Received a physician referral for a screening colonoscopy;
- Has access to a tablet, smartphone, or computer with working Internet.
Exclusion Criteria
- Hearing or vision impaired;
- Aim 1 or 2 participant.
Data sourced from ClinicalTrials.gov (NCT04987788). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.